Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: Correlations with clinicobiologic parameters

Blood

Volumn 119, Issue 10, 2012, Pages 2310-2313

  Rigolin, Gian Matteo ^a   Cibien, Francesca ^a   Martinelli, Sara ^a   Formigaro, Luca ^a   Rizzotto, Lara ^a   Tammiso, Elisa ^a   Saccenti, Elena ^a   Bardi, Antonella ^a   Cavazzini, Francesco ^a   Ciccone, Maria ^a   Nichele, Ilaria ^b   Pizzolo, Giovanni ^b   Zaja, Francesco ^c   Fanin, Renato ^c   Galieni, Piero ^d   Dalsass, Alessia ^d   Mestichelli, Francesca ^d   Testa, Nicoletta ^d   Negrini, Massimo ^e   Cuneo, Antonio ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d Ospedale Mazzoni   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGENIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 84858017452     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-395269     Document Type: Article

References (19)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8): 804-815.
2. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
3. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799-804. (Pubitemid 350010635)
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
6. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003; 101(12):4944-4951. (Pubitemid 36857758)
7. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323(11):720-724. (Pubitemid 20288941)
8. Cavazzini F, Hernandez JA, Gozzetti A, et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol. 2008;142(4):529-537. (Pubitemid 352020210)
9. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
10. Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108(9):3152-3160.
11. Haferlach C, Dicker F, Schnittger S, et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia. 2007; 21(12):2442-2451. (Pubitemid 350148886)
12. Hallek M, Cheson BD, Catovsky D, et al International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
13. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640-1645. (Pubitemid 24323778)
14. Rigolin GM, Maffei R, Rizzotto L, et al. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance. Cancer. 2010;116(8):1926-1937.
15. Bardi A, Cavazzini F, Rigolin GM, et al. Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma. J Biomed Biotechnol. 2011; 2011:691493.
16. Cuneo A, Rigolin GM, Bigoni R, et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia. 2004;18(3):476-483. (Pubitemid 38425861)
17. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009; 15(3):995-1004.
18. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
19. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16):2223-2229.